Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2002-5-16
pubmed:abstractText
Psoralen plus ultraviolet A irradiation (PUVA) has immunomodulatory effects and is used to treat a variety of immune-mediated dermatologic diseases. We administered PUVA to 103 patients for treatment of steroid-resistant acute graft-versus-host disease (GVHD) of the skin. Twenty-nine patients had related donors (12 HLA-mismatched) and 74 had unrelated donors (23 HLA-mismatched). The median onset of GVHD was day 13 after transplantation, and the median onset of PUVA treatment was day 46. PUVA was administered as secondary therapy for 86 patients and tertiary therapy or greater for 17 patients. The median number of treatments was 16, and the mean cumulative exposure was 41 J/cm2. PUVA was generally well tolerated with 8 patients discontinuing therapy because of toxicity. At the start of PUVA treatment, 48 patients had rash affecting >50% of their body surface area (BSA), and 91 had rash involving >25% BSA. Of 65 patients who were evaluated after 6 weeks of PUVA treatment, 11 still had rash involving >50% BSA, 24 had rash involving >25% BSA, and 24 had no rash. The mean daily dose of prednisone at the start of PUVA therapy was 1.6 mg/kg compared to 0.7 mg/kg after 6 weeks of therapy. Fifty-nine patients (57%) did not require additional therapy for skin GVHD after starting PUVA. Ninety-two percent of patients developed chronic GVHD. Fifty-three patients (51%) remain alive at 129-1883 days after transplantation. These results suggest that PUVA can be an effective therapy for steroid-resistant acute GVHD of the skin.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1083-8791
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
206-12
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:12014809-Acute Disease, pubmed-meshheading:12014809-Adolescent, pubmed-meshheading:12014809-Adult, pubmed-meshheading:12014809-Anemia, Refractory, with Excess of Blasts, pubmed-meshheading:12014809-Bone Marrow Transplantation, pubmed-meshheading:12014809-Child, pubmed-meshheading:12014809-Child, Preschool, pubmed-meshheading:12014809-Dermatitis, Phototoxic, pubmed-meshheading:12014809-Drug Resistance, pubmed-meshheading:12014809-Exanthema, pubmed-meshheading:12014809-Female, pubmed-meshheading:12014809-Graft vs Host Disease, pubmed-meshheading:12014809-Hematologic Neoplasms, pubmed-meshheading:12014809-Humans, pubmed-meshheading:12014809-Infant, pubmed-meshheading:12014809-Male, pubmed-meshheading:12014809-Middle Aged, pubmed-meshheading:12014809-PUVA Therapy, pubmed-meshheading:12014809-Peripheral Blood Stem Cell Transplantation, pubmed-meshheading:12014809-Prednisone, pubmed-meshheading:12014809-Radiation Injuries, pubmed-meshheading:12014809-Recurrence, pubmed-meshheading:12014809-Retrospective Studies, pubmed-meshheading:12014809-Safety, pubmed-meshheading:12014809-Transplantation, Homologous, pubmed-meshheading:12014809-Treatment Outcome
pubmed:year
2002
pubmed:articleTitle
Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease.
pubmed:affiliation
Fred Hutchinson Cancer Research Center, and the Department of Medicine, University of Washington, Seattle 98109-1024, USA. tfurlong@fhcrc.org
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.